Literature DB >> 15172464

Long-term, cause-specific mortality after myocardial infarction in diabetes.

Jorik R Timmer1, Jan Paul Ottervanger, Karen Thomas, Jan C A Hoorntje, Menko-Jan de Boer, Harry Suryapranata, Felix Zijlstra.   

Abstract

AIMS: To compare long-term, cause-specific mortality after reperfusion therapy for ST segment elevation myocardial infarction (STEMI) in patients with and without diabetes. METHODS AND
RESULTS: Patients with STEMI (n = 395) were randomised to intravenous streptokinase (SK) or primary percutaneous coronary intervention (PCI). Median follow-up was 7.5 years (interquartile range 5.6-8.5). A total of 74 patients (19%) had diabetes. Reduced left ventricular ejection fraction (<40%) after STEMI was more often observed in patients with diabetes (27% vs. 15%, P = 0.02). Patients with diabetes had a higher total mortality compared to patients without diabetes (HR 2.4; P < 0.001). Multivariate analysis confirmed that diabetes was an independent risk factor for long-term mortality (HR 2.3; P < 0.001). The incidence of sudden death was comparable in both patient groups (HR 1.6; P = 0.23). The increased mortality in patients with diabetes was mainly caused by heart failure (HR 3.1; P = 0.004). In patients with diabetes, primary PCI was associated with an improved prognosis.
CONCLUSIONS: Despite reperfusion therapy, STEMI patients with diabetes have an increased long-term mortality. This is due to death by heart failure and not by an increase in sudden death. Primary PCI is associated with an improved prognosis, particularly in patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172464     DOI: 10.1016/j.ehj.2004.04.001

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

1.  Primary percutaneous coronary intervention for patients with acute ST elevation myocardial infarction with and without diabetes mellitus.

Authors:  R J van der Schaaf; J P S Henriques; J J Wiersma; K T Koch; J Baan; K J J Mulder; J D Durrer; J G P Tijssen; J J Piek; R J de Winter
Journal:  Heart       Date:  2005-05-12       Impact factor: 5.994

2.  Coronary revascularization in diabetic patients: Current state of evidence.

Authors:  Mukesh Singh; Rohit Arora; Vamsi Kodumuri; Sandeep Khosla; Evyan Jawad
Journal:  Exp Clin Cardiol       Date:  2011

3.  Decade-long trends in the characteristics, management and hospital outcomes of diabetic patients with ST-segment elevation myocardial infarction.

Authors:  Mayra Tisminetzky; Samuel Joffe; David D McManus; Chad Darling; Joel M Gore; Jorge Yarzebski; Darleen Lessard; Robert J Goldberg
Journal:  Diab Vasc Dis Res       Date:  2014-03-11       Impact factor: 3.291

4.  PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?

Authors:  Siripong Palee; Siriporn Chattipakorn; Arintaya Phrommintikul; Nipon Chattipakorn
Journal:  World J Cardiol       Date:  2011-05-26

5.  The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies.

Authors:  Sachin Yende; Tom van der Poll; Minjae Lee; David T Huang; Anne B Newman; Lan Kong; John A Kellum; Tamara B Harris; Doug Bauer; Suzanne Satterfield; Derek C Angus
Journal:  Thorax       Date:  2010-10       Impact factor: 9.139

6.  Value of oral glucose tolerance test in the acute phase of myocardial infarction.

Authors:  Agata Bronisz; Marek Kozinski; Przemyslaw Magielski; Tomasz Fabiszak; Joanna Gierach; Iwona Swiatkiewicz; Adam Sukiennik; Aldona Kubica; Marek Bronisz; Zofia Grabczewska; Anna Sinkiewicz; Roman Junik; Jacek Kubica
Journal:  Cardiovasc Diabetol       Date:  2011-03-11       Impact factor: 9.951

7.  Diabetes mellitus and glucose as predictors of mortality in primary coronary percutaneous intervention.

Authors:  Renato Budzyn David; Eduardo Dytz Almeida; Larissa Vargas Cruz; Juliana Cañedo Sebben; Ivan Petry Feijó; Karine Elisa Schwarzer Schmidt; Luísa Martins Avena; Carlos Antonio Mascia Gottschall; Alexandre Schaan de Quadros
Journal:  Arq Bras Cardiol       Date:  2014-09-12       Impact factor: 2.000

8.  In-hospital daily insulin dose predicts long-term adverse outcome in patients with diabetes with ST-elevation myocardial infarction treated with successful primary percutaneous angioplasty.

Authors:  Tomasz Jeżewski; Jan Z Peruga; Jarosław D Kasprzak; Tomasz Bendinger; Michal Plewka; Jarosław Drożdż; Józef Drzewoski; Maria Krzeminska-Pakula
Journal:  Arch Med Sci       Date:  2014-10-23       Impact factor: 3.318

9.  Diabetes mellitus exacerbates post-myocardial infarction heart failure by reducing sarcolipin promoter methylation.

Authors:  Zhongwei Liu; Yong Zhang; Chuan Qiu; Haitao Zhu; Shuo Pan; Hao Jia; Hongyan Kang; Gongchang Guan; Rutai Hui; Ling Zhu; Junkui Wang
Journal:  ESC Heart Fail       Date:  2020-06-11

10.  Short- and long-term mortality after acute myocardial infarction: comparison of patients with and without diabetes mellitus.

Authors:  H L Koek; S S Soedamah-Muthu; J W P F Kardaun; E Gevers; A de Bruin; J B Reitsma; M L Bots; D E Grobbee
Journal:  Eur J Epidemiol       Date:  2007-10-10       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.